Study aim: Determination of Silymarin therapeutic effect in multiple Sclerosis patients receiving CinnoVex Design: In this study, 60 patients with Multiple Sclerosis who have been admitted to Kashani Hospital in Isfahan are selected. Participants are randomly divided into intervention and control groups and each participant is assigned a code. Settings and conduct: Patients referring to the Kashani hospital in Isfahan must be approved by the neurologist for the diagnosis of multiple sclerosis. Perform all stages of the test with patients satisfaction. These multiple sclerosis patients will be included in a randomized, double blind clinical trial. Participants/Inclusion and exclusion criteria: Inclusion criteria: The study population is among people with multiple sclerosis who are in the Kashani medical center in Isfahan, who use Synovox drug for less than 1 year. Exclusion criteria: Patients with multiple sclerosis treated with other interferon beta drugs and immunosuppressive drugs, as well as patients who have already received sinoox and their treatment discontinued, are excluded. Intervention groups: Intervention group: Patients with Multiple Sclerosis treated with CinnoVex and Silymarin Control group: Patients with multiple sclerosis treated with CinnoVex and placebo Main outcome variables: Serum levels of interleukin 10, 17, 23, 35; Serum interferon-gamma; Serum beta-growth factor